Le suivi thérapeutique pharmacologique

Couderc, Sylvain; Picard, Nicolas

doi:10.1016/j.actpha.2017.09.010

Cited by 2 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En raison d'une grande variabilité inter-et intra-individuelle de la cinétique, un suivi thérapeutique pharmacologique des immunosuppresseurs doit être envisagé [2]. TEG1 Le tacrolimus peut traverser la barrière foeto-placentaire au regard des observations menées sur la femme enceinte, mais des données issues de patientes transplantées n'ont pas mis en évidence de risque accru d'effets indésirables sur le déroulement et l'issue de la grossesse pendant le traitement, comparativement aux autres immunosuppresseurs.…”

Section: Encadré à Noterunclassified

Les immunosuppresseurs dans la prévention du rejet de greffe rénale

Clere

2019

Actualités Pharmaceutiques

View full text Add to dashboard Cite

Section: Encadré à Noterunclassified

Les immunosuppresseurs dans la prévention du rejet de greffe rénale

Clere

2019

Actualités Pharmaceutiques

View full text Add to dashboard Cite

“…T herapeutic drug monitoring (TDM) is the quantification of specific drugs in biological fluids, mainly in the blood, at defined time points. 1 TDM aims to maximize the treatment safety and efficacy by ensuring that the drug concentration remains in its therapeutic window. 1,2 Currently, only a fraction of therapies are used in combination with TDM, specifically those relying on drugs with (i) a narrow therapeutic index, (ii) severe consequences if under-or overdosing, (iii) large pharmacokinetics interpersonal variability, and when there is a good correlation between the drug blood concentration and its clinical effect.…”

mentioning

confidence: 99%

“…1 TDM aims to maximize the treatment safety and efficacy by ensuring that the drug concentration remains in its therapeutic window. 1,2 Currently, only a fraction of therapies are used in combination with TDM, specifically those relying on drugs with (i) a narrow therapeutic index, (ii) severe consequences if under-or overdosing, (iii) large pharmacokinetics interpersonal variability, and when there is a good correlation between the drug blood concentration and its clinical effect. 1−3 It is, for instance, essential or strongly advised to monitor certain antimicrobials (aminoglycosides, glycopeptides, azole antifungals), immunosuppressants, antiepileptics, antipsychotics, and anticancer drugs.…”

mentioning

confidence: 99%

“…Therapeutic drug monitoring (TDM) is the quantification of specific drugs in biological fluids, mainly in the blood, at defined time points . TDM aims to maximize the treatment safety and efficacy by ensuring that the drug concentration remains in its therapeutic window. , Currently, only a fraction of therapies are used in combination with TDM, specifically those relying on drugs with (i) a narrow therapeutic index, (ii) severe consequences if under- or overdosing, (iii) large pharmacokinetics interpersonal variability, and when there is a good correlation between the drug blood concentration and its clinical effect. − It is, for instance, essential or strongly advised to monitor certain antimicrobials (aminoglycosides, glycopeptides, azole antifungals), immunosuppressants, antiepileptics, antipsychotics, and anticancer drugs. − In oncology practice, where the highest tolerated doses are often administered to treat cancer, TDM is used to avoid excessive and life-threatening toxicity related to antineoplastic therapies. , …”

mentioning

confidence: 99%

See 1 more Smart Citation

Methotrexate Detection in Serum at Clinically Relevant Levels with Electrochemically Assisted SERS on a Benchtop, Custom Built Raman Spectrometer

et al. 2022

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) is an essential clinical practice for optimizing drug dosing, thereby preventing adverse effects of drugs with a narrow therapeutic window, slow clearance, or high interperson pharmacokinetic variability. Monitoring methotrexate (MTX) during high-dose MTX (HD-MTX) therapy is necessary to avoid potentially fatal side effects caused by delayed elimination. Despite the efficacy of HD-MTX treatment, its clinical application in resource-limited settings is constrained due to the relatively high cost and time of analysis with conventional analysis methods. In this work, we developed (i) an electrochemically assisted surface-enhanced Raman spectroscopy (SERS) method for detecting MTX in human serum at a clinically relevant concentration range and (ii) a benchtop, Raman detection system with an integrated potentiostat, software, and data analysis unit that enables mapping of small areas of SERS substrates and quantitative SERS-based analysis. In the assay, by promoting electrostatic attraction between gold-coated nanopillar SERS substrates and MTX molecules in aqueous samples, a detection limit of 0.13 μM with a linear range of 0.43−2 μM was achieved in PBS. The implemented sample cleanup through gel filtration proved to be highly effective, resulting in a similar detection limit (0.55 μM) and linear range (1.81−5 μM) for both PBS and serum. The developed and optimized assay could also be used on the in-house built, Raman device. We showed that MTX detection can be carried out in less than 30 min with the Raman device, paving the way toward the TDM of MTX at the pointof-need and in resource-limited environments.

show abstract

Le suivi thérapeutique pharmacologique

Cited by 2 publications

References 3 publications

Les immunosuppresseurs dans la prévention du rejet de greffe rénale

Les immunosuppresseurs dans la prévention du rejet de greffe rénale

Methotrexate Detection in Serum at Clinically Relevant Levels with Electrochemically Assisted SERS on a Benchtop, Custom Built Raman Spectrometer

Contact Info

Product

Resources

About